Holen Sie sich die Stockscreener-App
0.5204
1.10%
-0.0058
Handel nachbörslich:
.52
-0.0004
-0.08%
Schlusskurs vom Vortag:
$0.5262
Offen:
$0.525
24-Stunden-Volumen:
5,004
Relative Volume:
0.17
Marktkapitalisierung:
$3.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.72M
KGV:
-1.0839
EPS:
-0.4801
Netto-Cashflow:
$-4.88M
1W Leistung:
-3.58%
1M Leistung:
-5.72%
6M Leistung:
-31.97%
1J Leistung:
-67.48%
1-Tages-Spanne:
$0.5204
$0.525
1-Wochen-Bereich:
$0.487
$0.5577
52-Wochen-Spanne:
$0.4662
$1.85
Mustang Bio Inc Stock (MBIO) Company Profile
Firmenname
Mustang Bio Inc
Sektor
Branche
Telefon
(781) 652-4500
Adresse
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.5204 | 3.99M | 0 | -2.72M | -4.88M | -0.4801 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-10-02 | Eingeleitet | B. Riley FBR | Buy |
| 2019-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-08-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Mustang Bio Inc Aktie (MBIO) Neueste Nachrichten
EOCN Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
EOCN PE Ratio & Valuation, Is EOCN Overvalued - intellectia.ai
CAR T-cell Therapy for NHL Clinical Trial Landscape - GlobeNewswire
Altria, Pfizer, Healthpeak, Verizon: Outperformance and High Yield in One BasketEarnings Season Preview - dars.gov.et
Mustang Bio Stock Price Forecast. Should You Buy MBIO? - StockInvest.us
Mustang Bio Inc. (MBIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
Mustang Bio Inc. (MBIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Mustang (MBIO) Financial Results: The Bottom-Line Figure Trails Its Comparison; Post-Earnings: Shares Finish 1.11% Lower at the CloseEnergy Earnings Report - dars.gov.et
OFS (OCCIN) Levels: Finishes Nearly Flat at $24.93 on the Day; the Near-Term Reference Band Stretches From $23.68 to $26.18Volume Profile - careplusvn.com
Mustang (MBIO) EPS and Revenue: EPS Misses Its Estimate in the Latest Session; Market Response: The Market Price Moves 0.70% Higher in the Latest ReadingManagement Tone Analysis - vinanet.vn
Pediatrix (MD) Trading-Day Recap: Ends Higher by 0.84% at $26.56 on the Day; Level Position: Support at $25.23 and Resistance at $27.89 Frame the RangeReversal Trade - vinanet.vn
FSBC Q2 2026 Earnings: EPS Surpasses Estimates Despite Share DipCapex Guidance - vinanet.vn
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
BHE Q2 2026 Earnings: EPS Beats Estimates by 8.4% as Bottom-Line Strength Drives Shares HigherROIC Trend Report - Vinanet
Mustang Bio (MBIO) Edges Higher by 3% as Shares Test Key Resistance at $0.64Dark Pool Prints - Vinanet
Mustang Bio Inc. (MBIO) Holds Steady at $0.60 as Narrow Trading Range PersistsWMA Signal - careplusvn.com
Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Segment Evaluation and Major Growth Areas in the Viral Vector Production (Research-Use) Market - openPR.com
Leading Companies Consolidating Their Presence in the Viral Vector Manufacturing Market - openPR.com
Mustang Bio Q2 net loss widens 41% to $1.07 million - Bitget
MUSTANG BIO, INC. Q2 2026: Net income $(1.07)M, EPS $(0.16) — 10-Q Summary - TradingView
MBIO: Net loss widened, cash reserves declined, and Nasdaq delisting risk remains amid ongoing R&D focus - TradingView
Mustang Bio, Inc. (NASDAQ: MBIO) posts $2.0M loss and faces Nasdaq bid-price warning - Stock Titan
Mustang Bio, Inc. (MBIO) Net Income 2025: $1.9M net loss, up 87.8% - Stock Titan
Mustang Bio (MBIO) Holds $0.58 Support Zone as Gene Therapy Stock Ticks HigherPCR Moving Average - dars.gov.et
Fortress Biotech Just Netted $159 MillionIts Preferred Shares Could Be The Real Winner - Seeking Alpha
Glioblastoma Pipeline 2026: FDA Approvals, Therapies, - openPR.com
Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mustang Bio, Inc. Revenue Breakdown – NASDAQ:MBIO - TradingView
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mustang Bio Inc (MBIO) Cash Flow - TradingKey
MBIO|Mustang Bio Inc|Price:0.560|Chg%:-0.002 - TradingKey
TradingKey - TradingKey
Mustang Bio (MBIO) Slips Slightly as Stock Hovers Near Key Support ZonePCR Spike - careplusvn.com
Europe Gene Therapy Market Size, Growth & Forecast, 2034 - Market Data Forecast
Frontier tech research, news & data - MLQ.ai
Mustang Containment Solutions Acquires Mustang Extreme's Western and Southwestern Environmental Lining and Water Management Assets - Yahoo Finance
MBIO Q4 2024 Earnings: Significant EPS Miss Amid Pre-Revenue Biotech OperationsCore Business Growth - vinanet.vn
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Mustang Bio stock trades lower as cash runway and trial update shape outlook - Ad-hoc-news.de
Mesa Royalty Trust (MTR) Declines 2.2% as Stock Nears Critical Support at $2.95Shakeout Pattern - po-news-eg.net
MSN Money - MSN
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Amidst Ongoing Operational ChallengesBook Value Growth - careplusvn.com
Americore Resources Appoints Justin Hanka to Its Board of Directors - Moomoo
MBIO Q4 2024 Earnings: Massive EPS Miss as Losses WidenEarnings Surprise Score - vinanet.vn
AstraZeneca’s Clinical Setback Casts Doubt on Premium Valuation Amid Pipeline ConcernsMargin Expansion Trends - po-news-eg.net
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Deep Losses Overshadow Progress in CAR T PipelineGuidance Update - DonanımHaber
Mustang Bio (MBIO) Q1 2026 earnings summary - Quartr
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Operational ChallengesStrong Earnings Momentum - po-news-eg.net
Finanzdaten der Mustang Bio Inc-Aktie (MBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):